Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been well described....

Full description

Bibliographic Details
Main Authors: Harada Masao, Sukoh Noriaki, Asahina Hajime, Konishi Jun, Kinoshita Ichiro, Yamazaki Koichi, Yokouchi Hiroshi, Akie Kenji, Ogura Shigeaki, Ishida Takashi, Munakata Mitsuru, Dosaka-Akita Hirotoshi, Isobe Hiroshi, Nishimura Masaharu
Format: Article
Language:English
Published: BMC 2007-03-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/7/51

Internet

http://www.biomedcentral.com/1471-2407/7/51

Similar Items